Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
Slika profila

Željko Prka

27857

Željko

Prka

dr. sc.

nije evidentirano
Naziv Akcije
(KroHem) Mitrović, Zdravko ; Dujmović, Dino ; Jakšić, Ozren ; Bašić-Kinda, Sandra ; Gaćina, Petar ; Periša, Vlatka ; Prka, Željko ; Dreta, Barbara ; Galušić Davor ; Holik, Hrvoje et al. Dose-adjusted EPOCH and rituximab (DA-EPOCH-R) in older patients with high-risk aggressive diffuse large B-cell lymphoma: A real-life multicenter study by the Croatian Cooperative Group for Hematologic diseases (KroHem) // European journal of haematology, 111 (2023), 13957, 7. doi: 10.1111/ejh.13957
Lucijanić, Marko ; Huzjan Korunić, Renata ; Ivić, Marija ; Fazlić Džankić, Amina ; Jonjić, Željko ; Mitrović, Zdravko ; Prka, Željko ; Piršić, Mario ; Jakšić, Ozren ; Gaćina, Petar et al. Psoas muscle index at the time of diagnosis might reflect the prognosis of classical Hodgkinʼs lymphoma patients // Wiener klinische Wochenschrift, 134 (2022), 1-2; 80-82. doi: 10.1007/s00508-021-01850-x
Rončević, Pavle ; Mikulić, Mirta ; Prka, Željko ; Duraković, Nadira ; Ostojić, Alen ; Radić-Krišto, Delfa ; Desnica, Lana ; Perić, Zinaida ; Čaržavec, Dubravka ; Sertić, Dubravka et al. Smjernice za liječenje bolesnika s novodijagnosticiranom akutnom mijeloičnom leukemijom koji nisu podobni za liječenje intenzivnim oblicima liječenja // Bilten Krohema, 13 (2021), 2; 30-31
Pejsa, Vlatko ; Lucijanic, Marko ; Vrkljan Vuk, Anamarija ; Stoos-Veic, Tajana ; Jaksic, Ozren ; Jonjic, Željko ; Pirsic, Mario ; Prka, Željko ; Ivic, Marija ; Fazlic Dzankic, Amina et al. Prolonged methylprednisolone premedication prior to obinutuzumab in patients with chronic lymphocytic leukemia // Leukemia & lymphoma, 61 (2020), 4; 934-939. doi: 10.1080/10428194.2019.1702182
Lucijanić, Marko ; Mitrović, Zdravko ; Čičić, David ; Prka, Željko ; Pejša, Vlatko ; Livun, Ana ; Štoos‑Veić, Tajana ; Romić, Željko ; Živković, Marcela ; Lucijanić, Iva et al. Increased mean platelet volume (MPV) is an independent predictor of inferior survival in patients with primary and secondary myelofibrosis // International journal of hematology, 107 (2018), 2; 166-172. doi: 10.1007/s12185-017-2348-4
Lucijanic, Marko ; Prka, Zeljko ; Jaksic, Ozren ; Mitrovic, Zdravko ; Vrkljan, Anamarija ; Pejsa, Vlatko Bendamustine-based conditioning prior to autologous stem cell transplantation is associated with high rate of febrile neutropenia and higher mortality // American journal of hematology, 94 (2018), 2; E42-E43. doi: 10.1002/ajh.25340
Pejsa, Vlatko ; Lucijanic, Marko ; Jonjic, Zeljko ; Prka, Zeljko ; Vukorepa, Gorana Progressive multifocal leukoencephalopathy developing after obinutuzumab treatment for chronic lymphocytic leukemia // Annals of hematology, 98 (2018), 6; 1509-1510. doi: 10.1007/s00277-018-3552-x
Lucijanic, Marko ; Prka, Zeljko ; Pejsa, Vlatko ; Stoos-Veic, Tajana ; Lucijanic, Jelena ; Kusec, Rajko Prognostic implications of low transferrin saturation in patients with primary myelofibrosis // Leukemia research, 66 (2018), 89-95. doi: 10.1016/j.leukres.2018.01.017
Štoos-Veić, Tajana ; Aralica, Gorana ; Tomasović- Lončarić, Čedna ; Lucijanić, Marko ; Prka, Željko ; Mitrović, Zdravko ; Livun, Ana ; Novak, Nina Petra ; Škoro, Marija ; Kušec, Rajko Morfološki pokazatelji mutacijskog statusa bolesnika s esencijalnom trombocitemijom // LIJEČ VJESN 2017 ; 139 (suppl 2):45-45. 2017. str. 45-45
Pejša, Vlatko ; Prka, Željko ; Lucijanić, Marko ; Mitrović, Zdravko ; Piršić, Mario ; Jakšić, Ozren ; Ajduković, Radmila ; Kušec, Rajko Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients // Croatian medical journal, 58 (2017), 1; 40-48. doi: 10.3325/cmj.2017.58.40
nije evidentirano
nije evidentirano